May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Comparison of Tobradex (Tobramycin/Dexamethasone) and Zylet (Tobramycin/Loteprednol) in the Management of Blepharo–Keratoconjunctivitis
Author Affiliations & Notes
  • S.S. Rhee
    Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, UPMC Eye Center, Ophthalmology and Visual Science Research Center, Pittsburgh, PA
  • F.S. Mah
    Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, UPMC Eye Center, Ophthalmology and Visual Science Research Center, Pittsburgh, PA
  • Footnotes
    Commercial Relationships  S.S. Rhee, None; F.S. Mah, Alcon Labs, Inc., F; Allergan, Inc., F.
  • Footnotes
    Support  NIH Grant P30–EY008098, Research to Prevent Blindness, The Eye and Ear Foundation (Pittsburgh)
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4965. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.S. Rhee, F.S. Mah; Comparison of Tobradex (Tobramycin/Dexamethasone) and Zylet (Tobramycin/Loteprednol) in the Management of Blepharo–Keratoconjunctivitis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4965.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Previously, we reported on a comparison of two regimens (tobramycin/dexamethasone, Tobradex® Suspension [Alcon Laboratories, Ft. Worth, TX] and tobramycin/loteprednol, extemporaneously formulated) on the ability to rapidly control external ocular inflammation. In this clinical trial, we compared the ability of two commercially formulated antibiotic–steroid combinations, Tobradex® Suspension and ZyletTM (Bausch & Lomb Inc., Rochester, NY) to rapidly control the inflammation in blepharo–keratoconjunctivitis.

Methods: : This was a randomized, parallel–group, double masked study in forty eyes of forty patients with blepharo–keratoconjunctivitis. Patients received either tobramycin/loteprednol 0.5%, ZyletTM (ZYL) or tobramycin/dexamethasone 0.1%, Tobradex® (TBD) twice daily in the test eye according to the randomization schedule. At baseline, the ocular surface was graded on a scale of 3 (extensive) to 0 (minimum) for 4 components: blepharitis, ocular discharge, conjunctivitis, and corneal punctate epithelial keratopathy (PEK). Only those patients with at least moderate inflammation (cumulative score greater than 6) were included in the study. At follow–up 3–5 days later, the ocular surface was re–graded to evaluate treatment response. The individual and total scores were then compared between the two treatment groups using the Student’s t–test.

Results: : There was no statistical difference in pre–treatment scores for the 4 components [blepharitis (p=0.31), discharge (p=0.62), conjunctivitis (p=1.0), and PEK (p=0.57)] or total ocular inflammation score between the two groups (p=0.87). Mean post–treatment scores are reported: post–ZYL and post–TBD, with p values. Total ocular surface scores (sum of 4 components) 3.4 and 1.8 (p=0.002). Blepharitis scores 1.35 and 0.9 (p=0.017). Discharge scores 0.6 and 0.2 (p=0.024). Conjunctivitis scores 0.6 and 0.15 (p=0.013). Corneal PEK scores 0.85 and 0.55 (p=0.065). The mean time to follow up was 3.65 and 3.5 days (p=0.576). There was no change in intraocular pressure (p=0.88) or visual acuity (p=0.782) between the two groups. There were no adverse events.

Conclusions: : In this study of blepharo–keratoconjunctivitis, the two regimens provided a comparable rapid decrease in corneal PEK. However, Tobradex® Suspension significantly decreased clinical signs of ocular inflammation (i.e., blepharitis, discharge, conjunctivitis) and total ocular inflammation scores when compared with ZyletTM.

Keywords: conjunctivitis • antibiotics/antifungals/antiparasitics • anterior segment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×